Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis - European Journal of Cancer
the ONA take:
A systematic review of prospective randomized controlled trials was conducted to compare cardiotoxicity of anthracyclines in patients with breast cancer. Anthracyclines play a broad and important role in operable or metastatic breast cancer; however, cardiotoxicity can lead to potentially clinically meaningful treatment delays or discontinuations.
In this study, MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials and Google Scholar were searched for prospective randomized controlled trials comparing nonanthracycline based regimens (NON), doxorubicin (DOX), epirubicin (EPI), and liposomal doxorubicin (LD). Primary outcome measure was cardiac events grade 3 or greater (CE3) based on Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0. The search produced 19 trials that met eligibility criteria and were included in this Bayesian network meta-analysis.
Study findings indicate that CE3 rates were higher with DOX than with NON. LD statistically trended to lower cardiac event rates than DOX and appears to be the least cardiotoxic. Overall, incidence of CE3 with any type of anthracycline was low, and these drugs can be safely administered if cumulative dose limits are not exceeded.
Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in br
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|